How Excessive Data Collection Is Undermining Clinical Trials

Nearly one-third of data collected in clinical trials—amounting to over 600% more points than in 2005—does not directly influence regulatory or commercial decisions, yet patients continue to provide it without benefit. The finding, published in December 2025 by the Tufts Center for the Study of Drug Development in collaboration with TransCelerate, exposes a systemic inefficiency in pharmaceutical R&D that inflates costs, delays treatments, and burdens participants. With Phase III trials now averaging 200% more endpoints than a decade ago, the industry’s relentless pursuit of “more data” risks becoming its own worst enemy.

Key Clinical Takeaways:

• 30% of trial data is redundant: A Tufts-TransCelerate analysis found that nearly one-third of collected data fails to inform key decisions, yet patients still provide it—often without consent clarity.
• Protocol bloat is accelerating: Since 2005, procedures per protocol have surged 140%, endpoints 200%, and data points collected by over 600%, driven by pharma’s “more is better” mentality.
• Regulatory inertia persists: While the FDA and EMA have issued guidance on trial efficiency, adoption remains uneven, leaving gaps in how sponsors prioritize data relevance.

Why Are Pharma Companies Collecting Data That Doesn’t Matter?

The problem stems from a fundamental misalignment between industry incentives and patient-centered trial design. “Pharma’s culture rewards breadth over precision,” says Dr. Elena Vasquez, PhD, Director of Clinical Trial Optimization at the Tufts Center for the Study of Drug Development. “When a trial collects 600 data points instead of 100, the sponsor can point to a thicker dossier—but 30% of those points may not move the needle on approval or pricing negotiations.”

This inefficiency isn’t just academic. A 2024 study in Nature Reviews Drug Discovery estimated that for every dollar spent on clinical trials, $0.30 is wasted on irrelevant data collection. The financial toll is staggering: Deloitte projected in 2023 that the average cost per trial now exceeds $40 million, with data redundancy contributing 12–18% of that total.

The root cause? Regulatory ambiguity. While the FDA’s 2022 guidance on trial efficiency encourages sponsors to justify endpoints, enforcement remains inconsistent. “The EMA’s approach is slightly more prescriptive,” notes Dr. Mark Reynolds, PhD, Head of Global Regulatory Affairs at AstraZeneca, “but even there, sponsors often err on the side of over-collection to avoid post-approval scrutiny.”

How Did We Get Here? The Timeline of Trial Inflation

The trajectory began in the mid-2000s, when the FDA’s 2005 ICH E6(R1) guidance introduced stricter data integrity requirements. While intended to improve safety, the rule’s emphasis on “comprehensive documentation” created perverse incentives. By 2010, sponsors began embedding exploratory endpoints—data points collected for future analyses but not required for approval—into core protocols. A 2015 JAMA study found that 42% of Phase III trials included such endpoints, often without patient consent transparency.

The problem worsened with the rise of real-world evidence (RWE). Pharma companies now treat trials as “data factories,” collecting biospecimens, wearables, and longitudinal outcomes to feed post-marketing studies. “The average trial now generates 1.2 terabytes of data per patient, yet only 20% of that is used for the primary objective,” says Dr. Vasquez. “The rest sits in silos, unused.”

What’s the Human Cost of Data Overload?

Patients bear the brunt. A 2026 survey by the Patient-Centered Outcomes Research Institute (PCORI) revealed that 68% of trial participants reported fatigue from excessive data collection, with 22% dropping out prematurely due to burden. The emotional toll is compounded by consent ambiguity: many patients sign on for a 6-month study only to discover they’re being asked for blood draws, genetic sequencing, or 24/7 wearables—procedures not disclosed upfront.

For vulnerable populations, such as pediatric or geriatric cohorts, the risks are acute. A 2025 NEJM analysis found that trials with >300 data points had a 35% higher dropout rate in these groups. “We’re seeing a two-tiered system,” says Dr. Priya Mehta, MD, Director of Pediatric Clinical Trials at Boston Children’s Hospital. “[Sponsors] collect everything they can from healthy adults, but when it comes to kids or the elderly, they cut corners on what’s truly necessary.”

Who’s Fixing the Problem? The Rise of “Smart Trials”

Industry leaders are pushing back. The TransCelerate BioPharma Initiative, which co-authored the Tufts report, has launched a Data Minimization Framework to help sponsors right-size protocols. Key strategies include:

• Endpoint rationalization: Using FDA’s 2022 guidance to eliminate exploratory endpoints unless tied to a clear regulatory or commercial hypothesis.
• Adaptive designs: Pharma companies like Pfizer and Moderna are adopting master protocols that allow for real-time data triage, reducing redundant collection by up to 40%.
• Patient-centric consent: The U.S. Office for Human Research Protections (OHRP) now requires sponsors to disclose all data collection procedures upfront, with opt-out clauses for non-essential procedures.

Yet adoption remains patchy. “Only 12% of Phase III trials launched in 2025 used adaptive designs,” says Dr. Reynolds. “The rest are still stuck in the ‘collect everything’ mindset.”

What Happens Next? The Regulatory and Industry Crossroads

The EMA’s 2026 adaptive trial guidance may accelerate change, but pharma’s inertia is a hurdle. Meanwhile, AI-driven trial optimization tools—like those from Insitro—are emerging to predict which data points will matter most before collection begins. “By 2028, we expect AI to reduce redundant data collection by 25–30%,” predicts Dr. Vasquez.

For patients and sponsors alike, the path forward lies in collaborative trial design. Clinics specializing in protocol streamlining—such as [Relevant Clinic/Professional/Service: Clinical Trials Consulting Group]—are helping sponsors align data collection with regulatory expectations and patient tolerance. Meanwhile, healthcare compliance attorneys—like those at [Relevant Clinic/Professional/Service: Health Law Partners]—are advising on how to navigate the OHRP’s new consent rules without derailing trials.